Sarepta Therapeutics Inc
SRPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.87B
Close$
$153.22
764.2% upside
Current Fair Value
764.2% upsideUndervalued by 764.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.87 Billion |
|---|---|
| Enterprise Value | $2.46 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.13 |
| Beta | 0.21 |
| Outstanding Shares | 105,431,000 |
Return
| Return on Equity | -17.42% |
|---|---|
| Return on Assets | -8.35% |
| Return on Invested Capital | -8.04% |
Valuation & Multiples
| P/E Ratio | -12.31 |
|---|---|
| PEG | 12.01 |
| Price to Sales | 0.99 |
| Price to Book Ratio | 1.27 |
| Enterprise Value to Revenue | 1.24 |
| Enterprise Value to EBIT | -11.38 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.47 |
| Debt to Equity | 0.76 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$366.39 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$352.20 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 133.06% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.64%▼ 102.38% |
|---|---|
| Total Invested | $12.17M▼ 99.38% |
| Investors Holding | 40▼ 309.00% |
ESG Score
No data
About Sarepta Therapeutics Inc
835 employees
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...